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To assess the total medical costs and productivity losses
associated with the 1993 waterborne outbreak of cryp-
tosporidiosis in Milwaukee, Wisconsin, including the average
cost per person with mild, moderate, and severe illness, we
conducted a retrospective cost-of-illness analysis using data
from 11 hospitals in the greater Milwaukee area and epidemio-
logic data collected during the outbreak. The total cost of out-
break-associated illness was $96.2 million: $31.7 million in
medical costs and $64.6 million in productivity losses. The aver-
age total costs for persons with mild, moderate, and severe ill-
ness were $116, $475, and $7,808, respectively. The potential-
ly high cost of waterborne disease outbreaks should be consid-
ered in economic decisions regarding the safety of public drink-
ing water supplies.
C
ryptosporidium parvum, a protozoan parasite that causes
gastrointestinal illness, is transmitted by ingestion of
oocysts excreted in human or animal feces. Typical modes of
transmission include person to person, animal to person, by
exposure to contaminated surfaces, and by ingestion of impure
food or water (1). From 1990 to 2000, at least 10 cryp-
tosporidiosis outbreaks associated with contaminated drinking
water were reported in the United States (2–5). Although the
health impact of an outbreak of cryptosporidiosis originating
from a contaminated public water source has been carefully
documented (6), little effort has been made to estimate the eco-
nomic impact of such an outbreak. This study estimates the cost
of illness associated with perhaps the largest outbreak associat-
ed with a contaminated public water source ever reported in the
United States. In 1993, an estimated 403,000 residents of the
greater Milwaukee, Wisconsin, area (population, approximate-
ly 1.61 million) became ill when an ineffective filtration
process led to the inadequate removal of Cryptosporidium
oocysts in one of two municipal water treatment plants (6). We
assessed direct medical costs and productivity losses from diar-
rheal illness during the Milwaukee outbreak to estimate the
total cost of illness and the average cost per person with mild,
moderate, and severe illness.  
This cost-of-illness analysis was based on epidemiologic
data collected during and after the 1993 cryptosporidiosis out-
break in Milwaukee, Wisconsin. Primary data on utilization
and cost of inpatient admissions were obtained from a review
of medical and financial records from hospitals in the greater
Milwaukee area. 
Methods
Epidemiologic Burden of Illness
A telephone survey of 613 households provided estimates
on the total number of persons in Milwaukee experiencing
mild, moderate, or severe illness as a result of the cryp-
tosporidiosis outbreak (6). Cases were defined as residents of
Milwaukee County or the surrounding four counties
(Washington, Ozaukee, Racine, and Waukesha) with onset of
watery diarrhea from March 1 to April 28, 1993 (the outbreak
period). When disease case estimates were adjusted for normal
background diarrheal disease rates, investigators estimated that
403,000 residents of the five-county area experienced illness
caused by the cryptosporidiosis outbreak (6). Of this group, an
estimated 354,600 persons (~88%) did not seek medical atten-
tion; 44,000 persons (~11%) were seen as outpatients; and
4,400 persons (~1%) were hospitalized. 
Cost of Illness
Following the design of the epidemiologic studies of the
same outbreak, we categorized illness as mild, moderate, or
severe by type of medical care sought during the outbreak peri-
od and the following 2 months (4-month study period) when
persons were still likely to seek medical care (6–8). Persons
with mild illness did not seek physician or emergency depart-
ment care for their illness. Persons with moderate illness had at
least one physician or emergency department visit but were not
hospitalized. Persons with severe illness were hospitalized at
least once during this period.
Previous studies and evidence collected during the outbreak
suggest that underlying medical conditions such as AIDS can
increase the severity of illness in persons infected with
Cryptosporidium (9,10). To capture the effect of underlying
condition on cost of illness, we further classified patients with
moderate and severe illness as having no underlying condition,
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Data on utilization and average cost of inpatient services,
emergency department visits, ambulance transports, and med-
ication for persons with moderate and severe illness were
obtained from a review of medical and financial records from
11 of the 14 hospitals in the greater Milwaukee area. The three
nonparticipating hospitals did not differ in the number of con-
firmed cases of persons infected with Cryptosporidium, nor did
they serve specialty populations that would result in higher
medical costs per case. Total cost of illness was estimated from
average cost of illness multiplied by the burden of illness. All
clinical and financial data were recorded on standardized forms
and entered into a computerized database. We did not collect
information that identified patients by name or billing account
number. Additional data on use of services and costs for per-
sons with mild illness and data on productivity losses were
obtained from the City of Milwaukee Health Department and
published epidemiologic studies on the outbreak (6–8).
Cost-of-illness estimates for mild, moderate, and severe ill-
ness included both direct medical costs and indirect costs asso-
ciated with lost productivity. Medical costs included costs for
inpatient and outpatient health services, ambulance transport,
and medication. Productivity losses included time lost by
infected persons due to illness and the time lost by caregivers
or family members to tend to ill persons. All costs are present-
ed in 1993 U.S. dollars. We did not include litigation costs, the
cost of preventive measures (e.g., switching to bottled water),
intangible costs associated with pain and suffering, or the cost
to the local, state, and federal government to investigate and
control the outbreak.
Medical Costs
We used several parameters to estimate the direct medical
costs associated with diarrheal illness during the Milwaukee
cryptosporidiosis outbreak (Table 1). 
Inpatient and Emergency Department Health Care Costs
To assess the usage and average cost of inpatient admissions
(e.g., hospitalizations) and outpatient services associated with
emergency department visits, we reviewed all hospital medical
charts for persons with laboratory-confirmed cryptosporidiosis
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Table 1. Parameter estimates for calculating the cost of diarrheal illness during the cryptosporidiosis outbreak, Milwaukee, Wisconsin, 1993
a 
Parameter  Mild illness  Moderate illness  Severe illness 
% of infected persons with diarrhea  87.99 (6)  10.92 (6)  1.09 (6) 
Medical costs       
Inpatient healthcare costs       
   % with hospitalization  –  –  100 
   Cost of hospitalization  –  –  $6,312
b 
Outpatient healthcare costs       
   % with physician visit  –  95
c  29
b 
   Cost of physician visit  –  $45
d  $45
d 
   % with emergency department visit  –  5
b  –
 
   Cost of emergency department visit  –  $224
b  – 
Ambulance transport       
   % of emergency department visit/hospitalization with ambulance transport  –  4.9
b  16.3
b 
   Cost of ambulance transport  –  $228 (11)
c  $228 (11)
c 
Medication       
   Self-medication before seeking healthcare       








      Cost of medication  $5.73 (12)
c  $5.92 (12)
b  $6.74 (12)
b 
Medication prescribed after seeking healthcare       
   % taking medication  –  54
b  48
b 
   Cost of medication  –  $8.91 (12)
b  $70.52 (12)
b 
   Recurrent episodes       
      % with recurrent episodes (and assuming 100% take medication)  21 (7)  21 (7)  21 (7) 
      Duration of recurrent episodes, mean d  2 (8)  2 (8)  2 (8) 
      Cost of medication  $2.44 (12)
c  $2.44 (12)
c  $2.44 (12)
c 
Productivity losses       








   Earnings lost/d  $81 (13)  $81 (13)  $81 (13) 
aReference nos. are in parentheses. 
bMedical chart review. 
cAuthor assumption. 
dCity of Milwaukee Health Department.
 
eRandom digit dial survey conducted by the City of Milwaukee Health Department. as identified by the hospitals’ laboratory records. Because the
sensitivity of diagnostic testing is relatively low, and many per-
sons were not tested during the outbreak, we also reviewed a
sample of charts for persons admitted to the emergency depart-
ment or hospital with diarrhea for at least 2 days, as identified
by the following diagnostic codes from the International
Classification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) listed in one of the first four diagnosis categories
on the hospital discharge record: 007.20, 008.80, 009 and sub-
categories, 079.90, 234.10, 276 and subcategories, 558.90, and
999 and subcategories. During these admissions, either no lab-
oratory testing was performed or tests were negative for
Cryptosporidium and other intestinal pathogens. For the two
samples, we included all costs for the inpatient admission or
emergency department visit, regardless of whether the cost was
directly attributable to cryptosporidiosis. Charts were excluded
when the hospital admission was primarily for another condi-
tion (i.e., ICD-9-CM codes were not listed in one of the first
four diagnostic categories) and when the onset of gastrointesti-
nal illness occurred after hospital admission. 
From the medical records, we collected data on resource use
during hospitalization or emergency department visit, the use
of ambulance transportation, self-reported use of medication
before an emergency department visit or inpatient admission,
and physician-prescribed medication following an emergency
department visit or inpatient admission. Charges for hospital-
ization included diagnostic, laboratory, hospital room, and
technical services (e.g., physical therapy, occupational therapy,
and respiratory services); attending physician and nursing staff;
medication; emergency department services; and other supplies
or services not identified in the previous categories (e.g., med-
ical-surgical supplies, clinic services). 
Charges for emergency department visits and hospitaliza-
tions were converted to costs by using an average cost-to-
charge ratio of 0.67, based on ratios obtained from 6 of the 11
hospitals sampled in the greater Milwaukee area; this figure is
comparable to Wisconsin’s average operating cost-to-charge
ratio (0.70) reported for urban hospitals in 1993 (14). Charges
for specialty consultations not included in the hospital bill
were excluded from this analysis because insufficient data
were available on the number, duration, or charges for these
services.
Outpatient and Ambulance Costs
We assumed that 95% of persons with moderate illness
sought the care of a physician (one visit only) and that the
remaining 5% required an emergency department visit. (Data
collected from the epidemiologic investigation provided infor-
mation on whether ill persons sought healthcare for their illness
and whether they were hospitalized. No information was col-
lected on whether a nonhospitalized healthcare visit was to
seek physician or emergency department services. Therefore, in
the absence of reliable data, we assumed that 5% of persons
with moderate cryptosporidiosis went to the emergency depart-
ment). For the latter group, we assumed that no additional
physician visits were needed before or after the emergency
department visit. The proportion of persons with severe illness
who had a physician visit before hospitalization was obtained
from chart review. We assumed that one physician visit was
needed before (and none after) the hospitalization. The cost of
a physician visit ($45) was obtained from data collected by the
City of Milwaukee Health Department. (Since costs, and not
charges, for physician visits were provided, obtaining cost-to-
charge ratios was not necessary.) This figure is in the range
found by other studies that have estimated the cost of a physi-
cian visit as ranging from $40 (1992 dollars) to $53 (1994 U.S.
dollars) during this period (15,16).
Use of ambulance transport was indicated on the medical
charts for emergency department visits and hospitalizations.
Ambulance transport was used by 4.9% of those with moderate
illness involving an emergency department visit compared with
16.3% of those with serious illness. We used the 1993 rate set
by the City of Milwaukee ($185.50 for conveyance, $12 for
minor services, and $6 per mile) for the cost of an ambulance
transport, and we assumed that the average distance per trans-
port was 5 miles (11).
Medication Costs 
For mild illness, data regarding the duration of illness were
collected by the City of Milwaukee Health Department by
using a random digit dial survey. Methods for this data collec-
tion were published (6). For moderate and severe illness, data
regarding the duration of illness before an emergency depart-
ment visit or hospitalization, the percentage of persons self-
medicating during this period, and costs for medication were
obtained from the medical records. We assumed the percentage
of persons who self-medicated, as obtained from emergency
department records for a person with moderate illness, also
applied to persons with mild illness and to persons who did not
use the emergency department but sought other medical care. 
We estimated that all persons with mild illness who self-
medicated used four 2-mg tablets of loperamide antidiarrheal
medication per day or two 32-oz packs of oral rehydration solu-
tion per week, at a cost of $2.44/d. In the absence of reliable
data on the duration of self-medication for a person with mild
illness, we assumed that persons took medication for 50% of
the duration of illness. 
From the medical records, we collected detailed drug infor-
mation (i.e., type, quantity, and duration) for medications pre-
scribed upon discharge for persons with moderate and severe
illness. We assumed that medications prescribed for persons
with moderate illness seeking an emergency department visit
also applied to persons with moderate illness seeking physician
care. Retail drug prices in 1993 were used to calculate all costs
(12).
Data about recurrent illness for mild, moderate, and severe
illness were obtained from two investigations conducted during
the outbreak (7,8). On the basis of these data, we estimated that
21% of ill persons experienced a recurrent episode of diarrhea
for 2 days. As we did for persons with mild illness, we assumed
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the duration of illness at a cost of $2.44/d.
Productivity Losses
Productivity losses for ill persons and their caregivers were
estimated from data on days lost because of illness collected by
the random digit dial survey conducted by the City of
Milwaukee Health Department (6). In the absence of reliable
data on the days lost by caregivers of persons with severe ill-
ness, we assumed that a caregiver was needed for 50% of the
number of days hospitalized. The value of missed work time by
a caregiver or person with diarrheal illness was estimated by
using the average annual wages for residents of Wisconsin in
1993 (13), increased by 25% to include fringe benefits.
Because the type of day lost (i.e., work or leisure) was not spec-
ified in the secondary data available, we used an average daily
value of $81 (annual wage plus fringe benefits, divided by 365
days) (17). We valued the time of all persons based on the pro-
ductivity of the average worker, regardless of the work force
status of any person.
Results
We reviewed approximately 2,000 medical records from
October 30 through November 11, 1995, and identified 378
persons who met our case definition for a moderate or severe
case of cryptosporidiosis. We collected data on 155 persons
who met our case definition for a moderate illness (i.e., emer-
gency department visit only) and 223 persons who met our case
definition for severe illness (i.e., a hospitalization). Seventeen
percent of persons with moderate illness and 63% of persons
with severe illness in our sample had laboratory-confirmed
cryptosporidiosis.
Average costs of illness for persons with mild, moderate,
and severe illness were $116 for mild, $475 for moderate, and
$7,808 for severe (Table 2). Direct medical costs represented
2% of the average cost for persons with mild illness, 13% of
the average cost for persons with moderate illness, and 82% of
the average cost for persons with severe illness. The average
cost of illness for all persons who experienced diarrheal ill-
ness, weighted by the proportion in each illness category, was
$239 per person: $79 in medical costs and $160 in productiv-
ity losses.
The total cost of illness associated with the cryptosporidio-
sis outbreak in Milwaukee was approximately $96.2 million:
$31.7 million in direct medical costs and $64.6 million in pro-
ductivity losses (Table 3). Medical costs accounted for 33% of
the total cost of illness, including $790,760 for mild illness,
$2.7 million for moderate illness, and $28.2 million for severe
illness. Productivity losses accounted for 67% of the total cost
of illness, including $40.2 million for mild illness, $18.2 mil-
lion for moderate illness, and $6.2 million for severe illness.
Nearly 43% of all costs were attributable to persons with mild
illness, 22% to persons with moderate illness, and 36% to per-
sons with severe illness. 
Costs for Emergency Department Visits and
Hospitalizations by Underlying Condition
The average cost for an emergency department visit for per-
sons with moderate illness was $224 (Table 4). For persons
with no underlying condition (84% of emergency department
visits), the average cost for an emergency department visit was
$213. For persons with underlying conditions (only one patient
had AIDS), the average cost for an emergency department visit
was $265. The average cost for a hospitalization for persons
with severe illness was $6,312, with an average length of stay
of 8 days. For persons with no underlying condition (34% of
hospitalizations sampled), the average cost for a hospitalization
was $3,131, with an average length of stay of 5 days. For per-
sons with an underlying condition other than AIDS (52% of
hospitalizations that met the case definition), the average cost
for a hospitalization was $5,520, with an average length of stay
of 7 days. Persons with AIDS (14% of hospitalizations)
incurred the greatest average cost of hospitalization, $17,388,
with an average length of stay of 16 days.
Discussion
The massive waterborne outbreak of cryptosporidiosis in
1993 in Milwaukee caused illness in approximately 403,000
persons and generated substantial healthcare costs and produc-
tivity losses. We estimate that on average, ill persons incurred
approximately $79 in medical costs and $160 in productivity
losses, resulting in $31.7 million in total medical costs and
$64.6 million in total lost productivity. Since epidemiologic
estimates of incidence contribute substantially to total cost esti-
mates for any outbreak, information on average cost of illness
by severity can be applied to any range of epidemiologic esti-
mates to assess the sensitivity of total costs. For example, in the
Milwaukee outbreak, the 95% confidence interval for burden
(epidemiologic) of illness ranged from 370,000 to 435,000 per-
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losses ($)  Total ($) 
Mild   2  113  116 
Moderate   62  413  475 
Severe   6,399  1,409  7,808 
Average cost of illness  79  160  239 
aCosts in
 1993 United States dollars. 
bCosts may not add up due to rounding. 







losses ($)  Total ($) 
Mild (n=354,600)  790,760  40,212,000  41,002,000 
Moderate (n=44,000)  2,710,800  18,176,000  20,887,000 
Severe (n=4,400)  28,153,000  6,201,400  34,355,000 
Total cost of illness 
(n=403,000) 
31,655,000  64,589,000  96,244,000 
aCosts in 1993 United States dollars. 
bCosts may not add up due to rounding sons (2,400 to 6,400 for severe cases, and 38,000 to 50,000 for
moderate cases) (6). Applying these epidemiologic burden of
illness estimates to the average cost per case by severity, total
medical costs and productivity losses for the Milwaukee out-
break ranged from $75 to $118 million.
Although only 1% of persons who experienced diarrheal ill-
ness associated with the outbreak were hospitalized, their med-
ical costs accounted for 89% of the total outbreak-related med-
ical costs. Persons with suppressed immune systems were the
most severely affected, accounting for 66% of hospitalizations
and 74% of the total outbreak-related direct medical costs.
Persons with AIDS incurred hospital costs five times greater
than persons with no underlying condition. Persons with under-
lying conditions other than AIDS incurred almost twice the cost
of hospitalization compared with persons with no underlying
condition. 
During the 4-month period during and after the outbreak,
the productivity of Milwaukee residents and visitors who expe-
rienced diarrheal illness and their caregivers was severely
affected. Although mild illness did not represent a great strain
on the use of medical care resources, productivity losses were
substantial given the number of persons who experienced mild
illness that debilitated them in some capacity. Productivity loss-
es accounted for 98% of total costs for persons with mild ill-
ness and 87% of total costs for persons with moderate illness.
The cost-of-illness estimates in this study are conservative
for several reasons. Primary data collection from medical and
financial records limited our ability to assess all costs associat-
ed with the outbreak. For example, medical and financial
records lacked details about physician visits, ambulance trans-
ports, or self-medication before admission, and cost informa-
tion for professional services provided during hospitalization
that were billed separately. Further, an estimate of the magni-
tude of the occurrence of illness among visitors to the greater
Milwaukee area was not made. Conservative estimates were
used for any assumptions made when reliable data were not
available. Second, we excluded productivity losses associated
with chronic illness that might have extended beyond our 4-
month study period, and we also excluded productivity losses
associated with premature death. An estimated 69 deaths occur-
ring principally among persons with AIDS were attributed to
Milwaukee’s cryptosporidiosis outbreak (18). Excluding the
productivity losses associated with premature mortality poten-
tially underestimates our results for total productivity losses
associated with the outbreak.
While this study focused on the direct medical costs and
productivity losses for illness associated with the outbreak, a
broader perspective for the analysis would have included other
nonmedical costs for infected persons, costs to businesses, and
the cost to government agencies of controlling the outbreak and
improving the public water system. Costs to government agen-
cies alone, including the Centers for Disease Control and
Prevention (CDC), the Environmental Protection Agency, the
Wisconsin Division of Health (currently the Wisconsin
Division of Public Health), the City of Milwaukee Health
Department, the Milwaukee Water Works, and 17 local health
departments, were estimated at >$2 million immediately fol-
lowing the outbreak (CDC, unpublished data). A class action
suit filed by the residents of Milwaukee against the city contin-
ued to generate costs for the local government well beyond the
immediate outbreak period. Businesses similarly experienced
financial hardship during the outbreak because of employee ill-
ness, the necessity of using bottled water during the city’s boil-
water advisory, and a decrease in beverage and food sales over-
all. Unaccounted costs for the infected person include costs
incurred for self-protection (i.e., the purchase of bottled water)
and the pain and suffering associated with illness. 
Although the $96.2 million in illness costs attributed to the
Milwaukee outbreak is substantial, estimated monetized annu-
al costs of waterborne disease in the United States have been
estimated at $21.9 billion (1991 dollars) (19). This figure is
based on estimates of 7.1 million cases of mild to moderate
waterborne disease and 560,000 cases of severe disease (20),
and an average cost per case of $2,860, including medical costs
and productivity losses (21). (Average cost per case, $2,860, is
based on a study of a giardiasis outbreak in Pennsylvania in
1983–1984 [21]. Although the case-fatality ratio was lower
than in Milwaukee, the cost per case was higher than our esti-
mates because of a longer duration of illness.  The authors [19]
note that $2,860 likely overestimates the cost of a mild case and
underestimates the cost of a severe case.)  
In an era of limited health resources, decision makers must
choose how to allocate resources to improve the public’s
health. Measures taken to reduce the risk of waterborne cryp-
tosporidiosis will also prevent other waterborne diseases. Water
authorities often face the predicament of dealing with decreas-
ing raw water quality, the high costs of new technologies, water
filtration systems that do not completely remove all potentially
pathogenic organisms, and increased public demand for safe
water. The cost of this outbreak, which can be balanced against
the cost of measures for preventing future outbreaks,
1 is a
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Table 4. Average cost for emergency department visits and hospitalizations, by underlying condition
a 
  Emergency department visit ($)  Hospitalization ($)  Average length of stay(d) 
No underlying condition  213  3,131  5 
Underlying condition, other than AIDS  265  5,520  7 
AIDS  NA  17,388  16 
All conditions  224  6,312  8 
aCosts in 1993 United States dollars. 
1In 1998, the City of Milwaukee completed an $89 million renovation of two munic-
ipal water treatment plants, which together serve approximately 800,000 people,
as part of an effort to control future outbreaks of Cryptosporidium (22).reminder that failure to maintain safe drinking water supplies
has substantial impact on the health and economy of a commu-
nity. 
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